Devika Soundara Manickam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Devika Soundara Manickam has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Kandarp M. Dave
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282
17 shared publications- David Oupický
University of Nebraska Medical Center
15 shared publications Purva Khare
Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA 15282
12 shared publicationsDonna B. Stolz
Center for Biologic Imaging, University of Pittsburgh Medical School, Pittsburgh, PA, USA
9 shared publicationsSruti S. Shiva
Pittsburgh Heart Lung Blood Vascular Institute, University of Pittsburgh Medical School, Pittsburgh, PA 15213
8 shared publicationsParomita Paul Pinky
Duquesne University
7 shared publications
Latest Publications
- Open Access
Mitochondrial and bioenergetic processes are enriched in large- but are reciprocally depleted in small extracellular vesicles
Extracellular vesicles ( EVs ) are a promising class of drug delivery carriers for a broad range of therapeutic applications. We have previously demonstrated that brain endothelial cell ( BEC )-derived large EVs (>200 nm in particle diameter) increased mitochondrial function in recipient BECs and improved therapeutic outcomes in a mouse model of ischemic stroke. In the current study, we demonstrate using size-resolved quantitative proteomics and gene-set enrichment analysis that mitochondrial and bioenergetic processes are enriched in large- but are reciprocally depleted in small EVs (exosomes, <200 nm in particle diameter). These results are striking and reveal the selective packaging of mitochondrial cargo in large but not small EVs. These strong mechanistic data anchor the rationale for the continued development of large EV mitochondria as a potential approach for the treatment of multiple diseases associated with mitochondrial dysfunction.
Open AccessMitochondrial and bioenergetic processes are enriched in large- but are reciprocally depleted in small extracellular vesicles
Extracellular vesicles ( EVs ) are a promising class of drug delivery carriers for a broad range of therapeutic applications. We have previously demonstrated that brain endothelial cell ( BEC )-derived large EVs (>200 nm in particle diameter) increased mitochondrial function in recipient BECs and improved therapeutic outcomes in a mouse model of ischemic stroke. In the current study, we demonstrate using size-resolved quantitative proteomics and gene-set enrichment analysis that mitochondrial and bioenergetic processes are enriched in large- but are reciprocally depleted in small EVs (exosomes, <200 nm in particle diameter). These results are striking and reveal the selective packaging of mitochondrial cargo in large but not small EVs. These strong mechanistic data anchor the rationale for the continued development of large EV mitochondria as a potential approach for the treatment of multiple diseases associated with mitochondrial dysfunction.
- Open Access
Bioreactor cultures of brain endothelial cells produce extracellular vesicles with comparable characteristics as that of batch cultures
Our prior works have demonstrated the therapeutic potential extracellular vesicles (EVs) derived from batch cultures of brain endothelial cells (BECs) owing to their ability to transfer mitochondria to injured recipient cells. However, conventional batch/flask cultures limit scalable and reproducible production of EVs. Here, we evaluated a CELLine AD1000 bioreactor as a platform for sustained production of EVs from mouse b.End3 BECs and compared bioreactor-derived (BR) EVs with EVs obtained conventional batch cultures (BT). Large EVs (lEVs) and small (sEVs) were isolated using a sequential centrifugation protocol and were characterized using dynamic light scattering, nanoparticle tracking analysis, microBCA assay, western blotting, proteomics analysis, and their ability to rescue bioenergetics in oxygen-glucose deprived (OGD) BECs. Bioreactor cultures maintained high cell viabilities (~90%) for up to eight weeks and produced approximately three- to four-fold greater EV protein yields than batch cultures. BR EVs showed reproducible particle characteristics consistent with EV subtypes derived from BT cultures. CD63, CD9 and Arf6 were detected in EV fractions, whereas the mitochondrial outer-membrane protein TOMM20 was enriched in lEVs. Proteomic analyses revealed that bioreactor-derived lEVs retained the mitochondrial cargo signature observed in batch-derived lEVs. Both bioreactor and batch EVs restored relative ATP levels in ODG-exposed BECs. These findings suggest that bioreactor BEC cultures are a scalable approach for generating functionally active BEC-EVs for downstream characterization and therapeutic development.
Open AccessBioreactor cultures of brain endothelial cells produce extracellular vesicles with comparable characteristics as that of batch cultures
Our prior works have demonstrated the therapeutic potential extracellular vesicles (EVs) derived from batch cultures of brain endothelial cells (BECs) owing to their ability to transfer mitochondria to injured recipient cells. However, conventional batch/flask cultures limit scalable and reproducible production of EVs. Here, we evaluated a CELLine AD1000 bioreactor as a platform for sustained production of EVs from mouse b.End3 BECs and compared bioreactor-derived (BR) EVs with EVs obtained conventional batch cultures (BT). Large EVs (lEVs) and small (sEVs) were isolated using a sequential centrifugation protocol and were characterized using dynamic light scattering, nanoparticle tracking analysis, microBCA assay, western blotting, proteomics analysis, and their ability to rescue bioenergetics in oxygen-glucose deprived (OGD) BECs. Bioreactor cultures maintained high cell viabilities (~90%) for up to eight weeks and produced approximately three- to four-fold greater EV protein yields than batch cultures. BR EVs showed reproducible particle characteristics consistent with EV subtypes derived from BT cultures. CD63, CD9 and Arf6 were detected in EV fractions, whereas the mitochondrial outer-membrane protein TOMM20 was enriched in lEVs. Proteomic analyses revealed that bioreactor-derived lEVs retained the mitochondrial cargo signature observed in batch-derived lEVs. Both bioreactor and batch EVs restored relative ATP levels in ODG-exposed BECs. These findings suggest that bioreactor BEC cultures are a scalable approach for generating functionally active BEC-EVs for downstream characterization and therapeutic development.
- Open Access
- 22 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (5) , 1201-1216
Sequential- vs . density gradient-centrifugation for the isolation of mitochondria-containing extracellular vesicles
Large extracellular vesicles (lEVs) contain mitochondria. Despite loss of EV yields, lEVs purified via density gradient centrifugation increase recipient cell mitochondrial function compared to lEVs isolated via sequential ultracentrifugation.
- 22 September 2026
- Published by Royal Society of Chemistry (RSC) in RSC Pharmaceutics
- Vol. 3 (5) , 1201-1216
Open AccessSequential- vs . density gradient-centrifugation for the isolation of mitochondria-containing extracellular vesicles
Large extracellular vesicles (lEVs) contain mitochondria. Despite loss of EV yields, lEVs purified via density gradient centrifugation increase recipient cell mitochondrial function compared to lEVs isolated via sequential ultracentrifugation.
- Open Access
- 6 July 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (8) , 113315
Macrophage-specific targeting of histone demethylases with small-molecule inhibitors suppresses inflammatory response in vivo
- 6 July 2026
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 302 (8) , 113315
Open AccessMacrophage-specific targeting of histone demethylases with small-molecule inhibitors suppresses inflammatory response in vivo
- Open Access
- 24 December 2025
- Published by Elsevier in Extracellular Vesicle
- Vol. 7
Mitochondria-containing large extracellular vesicles target mouse motor neurons upon intramuscular injection
- 24 December 2025
- Published by Elsevier in Extracellular Vesicle
- Vol. 7
Open AccessMitochondria-containing large extracellular vesicles target mouse motor neurons upon intramuscular injection
- 30 November 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114487
Ionic liquid-coated lipid nanoparticles demonstrate prolonged circulation and brain uptake via red blood cell hitchhiking
- 30 November 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 389, 114487
Ionic liquid-coated lipid nanoparticles demonstrate prolonged circulation and brain uptake via red blood cell hitchhiking
- Open Access
Mitochondria-containing large extracellular vesicles target mouse motor neurons upon intramuscular injection
Amyotrophic Lateral Sclerosis ( ALS ) is a neurological disorder that causes progressive degeneration of motor neurons. Mitochondrial dysfunction accelerates neurodegeneration aggravating the severity of ALS. We hypothesized that increasing the mitochondrial function of motor neurons may promote neuronal survival. Therefore, we investigated the potential of neuron-derived mitochondria containing extracellular vehicles ( EVs ) as a novel therapeutic approach for ALS using differentiated NSC-34 cells as a surrogate for neurons. Neuron derived-large EVs ( lEVs ) but not small EVs ( sEVs ) contained mitochondria. However, we observed increased cell viability and oxygen consumption rates in heat-stressed neurons treated with both sEVs and lEVs suggesting improved mitochondrial function in recipient neurons. The increased oxygen consumption rates in sEV-treated heat-stressed neurons was accompanied by a greater proton leak compared to lEV treatment. The greater proton leak observed with sEVs likely suggests a lower efficiency of oxidative phosphorylation compared to that achieved by cells treated with mitochondria-containing lEVs. These findings suggest that mitochondrial components present in sEVs, such as proteins and mitochondrial DNA, may too contribute to improving cellular respiration. Furthermore, we have demonstrated that lEV mitochondria are transported into the lumbar spinal cord motor neurons following intramuscular injection in C57BL/6 mice in a EV dose-dependent manner. Collectively, for the first time, we have demonstrated the therapeutic effects of neuronal EVs in recipient heat-stressed neurons and the delivery of lEV mitochondria to spinal cord motor neurons in vivo without any EV surface modifications for neuronal targeting. Further studies will determine the therapeutic efficacy of mitochondria-containing EVs in the SOD1 G93A transgenic mouse model of ALS. Graphical
Open AccessMitochondria-containing large extracellular vesicles target mouse motor neurons upon intramuscular injection
Amyotrophic Lateral Sclerosis ( ALS ) is a neurological disorder that causes progressive degeneration of motor neurons. Mitochondrial dysfunction accelerates neurodegeneration aggravating the severity of ALS. We hypothesized that increasing the mitochondrial function of motor neurons may promote neuronal survival. Therefore, we investigated the potential of neuron-derived mitochondria containing extracellular vehicles ( EVs ) as a novel therapeutic approach for ALS using differentiated NSC-34 cells as a surrogate for neurons. Neuron derived-large EVs ( lEVs ) but not small EVs ( sEVs ) contained mitochondria. However, we observed increased cell viability and oxygen consumption rates in heat-stressed neurons treated with both sEVs and lEVs suggesting improved mitochondrial function in recipient neurons. The increased oxygen consumption rates in sEV-treated heat-stressed neurons was accompanied by a greater proton leak compared to lEV treatment. The greater proton leak observed with sEVs likely suggests a lower efficiency of oxidative phosphorylation compared to that achieved by cells treated with mitochondria-containing lEVs. These findings suggest that mitochondrial components present in sEVs, such as proteins and mitochondrial DNA, may too contribute to improving cellular respiration. Furthermore, we have demonstrated that lEV mitochondria are transported into the lumbar spinal cord motor neurons following intramuscular injection in C57BL/6 mice in a EV dose-dependent manner. Collectively, for the first time, we have demonstrated the therapeutic effects of neuronal EVs in recipient heat-stressed neurons and the delivery of lEV mitochondria to spinal cord motor neurons in vivo without any EV surface modifications for neuronal targeting. Further studies will determine the therapeutic efficacy of mitochondria-containing EVs in the SOD1 G93A transgenic mouse model of ALS. Graphical
- Top Cited Papers
- 26 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 386, 114068
Molecular engineering of extracellular vesicles for drug delivery: Strategies, challenges, and perspectives
- 26 July 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 386, 114068
Top Cited PapersMolecular engineering of extracellular vesicles for drug delivery: Strategies, challenges, and perspectives
- 11 June 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (2) , 306-321
Extracellular vesicle-mediated mitochondria delivery: Premise and promise
Mitochondrial transfer is highly significant under physiological as well as pathological states given the emerging recognition of mitochondria as cellular “processors” akin to microchip processors that control the operation of a mobile device. Mitochondria play indispensable roles in healthy functioning of the brain, the organ with the highest energy demand in the human body and therefore, loss of mitochondrial function plays a causal role in multiple brain diseases. In this review, we will discuss various aspects of extracellular vesicle ( EV )-mediated mitochondrial transfer and their effects in increasing recipient cell/tissue bioenergetics with a focus on these processes in brain cells. A subset of EVs with particle diameters >200 nm, referred to as medium-to-large EVs ( m/lEVs ), are known to entrap mitochondria during EV biogenesis. The entrapped mitochondria are likely a combination of either polarized, depolarized mitochondria or a mixture of both. We will also discuss engineering approaches to control the quality and quantity of mitochondria entrapped in the m/lEVs. Controlling mitochondrial quality can allow for optimizing/maximizing the therapeutic potential of m/lEV mitochondria—a novel drug with immense potential to treat a wide range of disorders associated with mitochondrial dysfunction.
- 11 June 2025
- Published by SAGE Publications in Journal of Cerebral Blood Flow & Metabolism
- Vol. 46 (2) , 306-321
Extracellular vesicle-mediated mitochondria delivery: Premise and promise
Mitochondrial transfer is highly significant under physiological as well as pathological states given the emerging recognition of mitochondria as cellular “processors” akin to microchip processors that control the operation of a mobile device. Mitochondria play indispensable roles in healthy functioning of the brain, the organ with the highest energy demand in the human body and therefore, loss of mitochondrial function plays a causal role in multiple brain diseases. In this review, we will discuss various aspects of extracellular vesicle ( EV )-mediated mitochondrial transfer and their effects in increasing recipient cell/tissue bioenergetics with a focus on these processes in brain cells. A subset of EVs with particle diameters >200 nm, referred to as medium-to-large EVs ( m/lEVs ), are known to entrap mitochondria during EV biogenesis. The entrapped mitochondria are likely a combination of either polarized, depolarized mitochondria or a mixture of both. We will also discuss engineering approaches to control the quality and quantity of mitochondria entrapped in the m/lEVs. Controlling mitochondrial quality can allow for optimizing/maximizing the therapeutic potential of m/lEV mitochondria—a novel drug with immense potential to treat a wide range of disorders associated with mitochondrial dysfunction.
- Open Access
Ionic liquid-coated lipid nanoparticles demonstrate prolonged circulation and brain uptake via red blood cell hitchhiking
Lipid nanoparticles ( LNPs ) have transformed the delivery of nucleic acid therapeutics; however, their natural tropism favors the liver resulting in clearance by the reticuloendothelial system, with less than 1% of the injected dose reaching challenging targets such as brain. Biocompatible ionic liquids ( ILs ) are tunable materials that can modulate nanoparticle interactions with blood components. Choline trans -2-hexenoate ( C2HA ) is an IL known to facilitate red blood cell ( RBC ) hitchhiking of PLGA polymeric nanoparticles and reduces hepatic uptake and therefore enabling transport to distant non-hepatic organs. We wanted to determine if C2HA coatings can show similar RBC hitchhiking effects with LNPs. We previously demonstrated that IL-coated LNPs reduce serum protein binding to LNPs—a key contributor to rapid clearance via the liver. While LNPs coated with choline trans -2-hexenoate at 1:1 and 1:2 cation: anion ratios decreased mouse serum protein binding and improved cellular uptake into brain endothelial cells ( BECs ) and motor neurons, they did not show hitchhiking behavior. To identify IL formulations capable of this behavior, we screened higher IL cation: anion ratios (1:3 and 1:5) for LNP coating and optimized IL volumes that allowed stable particle diameters. The resulting IL-coated LNPs successfully hitchhiked on both mouse and human RBCs and significantly enhanced uptake in b.End3 mouse BECs, and NSC-34 neuroblastoma cells compared to uncoated LNPs. 1:3 IL-coated LNPs demonstrated the most pronounced improvement in RBC binding. Whole blood pharmacokinetic and biodistribution analyses demonstrated that IL-coating significantly extends the circulation time of LNPs and results in reduced hepatic uptake alongside increased routing to the brain, compared to standard LNPs. These findings reveal that ILs can be leveraged to re-engineer clinically approved LNP platforms to promote RBC hitchhiking behavior and further be developed for drug delivery to challenging extra-hepatic targets such as the brain. Graphical
Open AccessIonic liquid-coated lipid nanoparticles demonstrate prolonged circulation and brain uptake via red blood cell hitchhiking
Lipid nanoparticles ( LNPs ) have transformed the delivery of nucleic acid therapeutics; however, their natural tropism favors the liver resulting in clearance by the reticuloendothelial system, with less than 1% of the injected dose reaching challenging targets such as brain. Biocompatible ionic liquids ( ILs ) are tunable materials that can modulate nanoparticle interactions with blood components. Choline trans -2-hexenoate ( C2HA ) is an IL known to facilitate red blood cell ( RBC ) hitchhiking of PLGA polymeric nanoparticles and reduces hepatic uptake and therefore enabling transport to distant non-hepatic organs. We wanted to determine if C2HA coatings can show similar RBC hitchhiking effects with LNPs. We previously demonstrated that IL-coated LNPs reduce serum protein binding to LNPs—a key contributor to rapid clearance via the liver. While LNPs coated with choline trans -2-hexenoate at 1:1 and 1:2 cation: anion ratios decreased mouse serum protein binding and improved cellular uptake into brain endothelial cells ( BECs ) and motor neurons, they did not show hitchhiking behavior. To identify IL formulations capable of this behavior, we screened higher IL cation: anion ratios (1:3 and 1:5) for LNP coating and optimized IL volumes that allowed stable particle diameters. The resulting IL-coated LNPs successfully hitchhiked on both mouse and human RBCs and significantly enhanced uptake in b.End3 mouse BECs, and NSC-34 neuroblastoma cells compared to uncoated LNPs. 1:3 IL-coated LNPs demonstrated the most pronounced improvement in RBC binding. Whole blood pharmacokinetic and biodistribution analyses demonstrated that IL-coating significantly extends the circulation time of LNPs and results in reduced hepatic uptake alongside increased routing to the brain, compared to standard LNPs. These findings reveal that ILs can be leveraged to re-engineer clinically approved LNP platforms to promote RBC hitchhiking behavior and further be developed for drug delivery to challenging extra-hepatic targets such as the brain. Graphical